Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-12 p35 siRNA
- Development stage
- Preclinical
- Lead developer
- ToleroTech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
IL-12 p35 siRNA is a preclinical-stage therapeutic candidate developed by ToleroTech. It utilizes small interfering RNA (siRNA) technology to silence the expression of the p35 subunit of interleukin-12 (IL-12) in dendritic cells. IL-12 is a key pro-inflammatory cytokine that drives the differentiation of Th1 cells and promotes cellular immunity. By inhibiting the production of the p35 subunit, which is required for the assembly of the bioactive IL-12p70 heterodimer, the drug aims to suppress pathological immune responses in autoimmune and immune-associated diseases. The program was identified in academic literature and secondary sources as part of ToleroTech's pipeline, although the company is currently reported as archived or defunct.
- Other names
- interleukin-12 p35 small interfering RNAinterleukin12 p35 small interfering RNAinterleukin 12 p35 small interfering RNAsiRNA targeting IL-12 p35IL-12 p35 subunit-siRNAIL12 p35 subunit-siRNAIL 12 p35 subunit-siRNA
02
Targets
IL12A (Interleukin-12 subunit alpha)
Beyond the preview
Go deeper on IL-12 p35 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-12 p35 siRNA.